Method of inhibiting ATF/CREB and cancer cell growth and...

Details Method of inhibiting ATF/CREB and cancer cell growth and... Method of inhibiting ATF/CREB and cancer cell growth and...

2003-05-14

2010-10-19

Anderson, James D (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

N-c doai

Reexamination Certificate

active

07816403

ABSTRACT:
There is provided a method for inhibiting ATF/CREB and cancer cell growth using disulfiram, administered in combination with heavy metals. It was found that disulfiram disrupts transcription factor DNA binding by forming mixed disulfides with thiols within the DNA-binding region, and that this process is facilitated by metal ions. Disulfiram administered to melanoma cells in combination with copper (II) or zinc(II) decreased expression of cyclin A, reduced proliferation in vitro, and inhibited growth of melanoma cells. The combination of oral zinc gluconate and disulfiram at currently approved doses for alcoholism stabilized tumor growth in two of three patients with Stage IV metastatic melanoma, with 12 and 17 month survivals, respectively, to date, and produced a >50% reduction in hepatic metastases in one individual.

REFERENCES:
patent: 2454541 (1948-11-01), Bock et al.
patent: 4039669 (1977-08-01), Beyler et al.
patent: 4066697 (1978-01-01), Lawrence
patent: 4144272 (1979-03-01), Bergomi et al.
patent: 4148885 (1979-04-01), Renoux et al.
patent: 4368223 (1983-01-01), Kobayashi et al.
patent: 4426372 (1984-01-01), Borch
patent: 4581224 (1986-04-01), Borch
patent: 4594238 (1986-06-01), Borch
patent: 4645661 (1987-02-01), Schonbaum
patent: 4762705 (1988-08-01), Rubin
patent: 4826821 (1989-05-01), Clements
patent: 4870101 (1989-09-01), Ku et al.
patent: 4999347 (1991-03-01), Sorenson
patent: 5002755 (1991-03-01), Mitchell et al.
patent: 5035878 (1991-07-01), Borch et al.
patent: 5037812 (1991-08-01), Berners-Price et al.
patent: 5166387 (1992-11-01), Hirschbein
patent: 5187193 (1993-02-01), Borch et al.
patent: 5206264 (1993-04-01), Marangos
patent: 5240914 (1993-08-01), Rubin
patent: 5294430 (1994-03-01), Borch et al.
patent: 5373021 (1994-12-01), Marangos
patent: 5380747 (1995-01-01), Medford et al.
patent: 5679777 (1997-10-01), Anderson et al.
patent: 5703130 (1997-12-01), Han et al.
patent: 5750351 (1998-05-01), Medford et al.
patent: 5759517 (1998-06-01), Anderson et al.
patent: 5773209 (1998-06-01), Medford et al.
patent: 5773231 (1998-06-01), Medford et al.
patent: 5783596 (1998-07-01), Medford et al.
patent: 5786344 (1998-07-01), Ratain et al.
patent: 5792787 (1998-08-01), Medford et al.
patent: 5824664 (1998-10-01), Schein et al.
patent: 5827880 (1998-10-01), Malfroy-Camine et al.
patent: 5877203 (1999-03-01), Medford et al.
patent: 5891633 (1999-04-01), Gonzalez et al.
patent: 5922757 (1999-07-01), Chojkier
patent: 6057111 (2000-05-01), Deiss et al.
patent: 6153603 (2000-11-01), Siren
patent: 6156794 (2000-12-01), Faiman et al.
patent: 6288110 (2001-09-01), Marikovsky
patent: 6469057 (2002-10-01), Lai
patent: 6548540 (2003-04-01), Kennedy
patent: 6589987 (2003-07-01), Kennedy
patent: 6649591 (2003-11-01), Lai
patent: 6660767 (2003-12-01), Jacobs et al.
patent: 6706759 (2004-03-01), Kennedy
patent: 6919425 (2005-07-01), Hong et al.
patent: 6987127 (2006-01-01), Kennedy
patent: 2002/0102604 (2002-08-01), Milne Edwards et al.
patent: 2007/0232692 (2007-10-01), Kennedy
patent: 2384059 (2001-03-01), None
patent: 2424761 (2002-04-01), None
patent: 0284879 (1988-10-01), None
patent: 1214063 (2005-07-01), None
patent: 0602702 (2006-09-01), None
patent: 2 081 094 (1982-02-01), None
patent: 2081094 (1982-02-01), None
patent: 4202139 (1992-07-01), None
patent: 4202139 (1992-07-01), None
patent: 11-021226 (1999-01-01), None
patent: WO 91/17766 (1991-11-01), None
patent: WO 95/30415 (1995-11-01), None
patent: WO 97/05867 (1997-02-01), None
patent: WO 97/05867 (1997-02-01), None
patent: WO 99/34763 (1999-07-01), None
patent: WO 99/34784 (1999-07-01), None
patent: WO 01/17522 (2001-03-01), None
patent: WO 01/17522 (2001-03-01), None
patent: WO 02/28349 (2002-04-01), None
Bertram et al, Environ, Carcino. & Ecotox. Revs., C11(1), 1-71, 1993.
MEDLINE AN 89350092, Craciunescu G et al, Anticancer res, May-Jun. 9, 1989, (3) 781-5, abstract.
CANCERLIT AN 93686628, Hacker M, The toxicity of anticancer drugs, Pergamon Press, 82-105, 1991, abstract.
Grandjean et al. Annals of Clinical and Laboratory Science, 1990, vol. 20, No. 1, pp. 28-35 (Abstract attached).
Soliman et al. Cellular and Molecular Life Sciences, 1975, vol. 31, No. 3, pp. 280-281.
Nobel, et al.; “Dithiocarbamates Induce Apoptosis in Thymocytes by Raising the Intracellular Level of Redox-active Copper”;The Journal of Biological Chemistry; vol. 270, No. 44, Nov. 3, pp. 26202-26208, 1995.
Johansson; “A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites”;Acta Psychiatr Scand,1992: 86: pp. 15-26.
Arnelle et al.; “Diethyl Dithiocarbamate-Induced Decomposition of S-Nitrosothiols”,nitric oxide: biology and Chemistry;February, pp. 56-64 (1997).
Verhaegh et al.; “Regulation of p53 by Metal Ions and by Antioxidants: Dithiocarbamate Down-Regulates p53 DNA-Binding Activity by Increasing the Intracellualar Level of Copper”;Molecular and Cellular Biology,vol. 17, No. 10, Oct. 1997, p. 5699-5706.
Schreck et al.; “Dithiocarbamates as Potent Inhibitors of Nuclear Factor κB Activation in Intact Cells”;J. Exp. Med.,vol. 175, May 1992, pp. 1181-1194.
Burns et al.; “1,1-Dithiolato Complexes of the Transition Elements”;Advances in Inorganic Chemistry and Radiochemistry,vol. 23, pp. 211-280, 1980.
Protective Effects ƒ Glutathione on Diethyldithiocarbamate(DDC)Cytotoxicity: A Possible Mechanism,L. D. Trombetta et al., Toxicology and Applied Pharmacology 93, pp. 154-164, 1988.
Inhibition of Meth-A Tumor Cell Proliferation in Combined Use of Disulfiram with Catalase,H. Mashiba et al., Toxicology Letters, 61, pp. 75-80, 1992.
Phase I Study of the Combination of Disulfiram with Cisplatin,D. J. Stewart et al., Am. J. Clin. Oncol. (CCT), vol. 10, No. 6, pp. 517-519, 1987.
Antitumour Activity of New Nitrosources on Yoshida Sarcoma Ascites Cells In Vivo,M. Habs et al., Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg, FRG, pp. 438-444, 1983.
A Review of the Modulation of Cisplatin Toxicities by Chemoprotectants,R. T. Dorr, Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, pp. 131-154, 1996.
Cytotoxic Interactions of Zn2+In Vitro: Melanoma Cells Are More Susceptible Than Melanocytes,J. Borovansky et al., Melanoma Research, vol. 7, pp. 449-453, 1997.
Database CAPLUS on STN (Columbus, OH) DN 136:379617, Cen D. et al., “Disulfiram induces apoptosis in human melanoma cells: a redox-related process”,Molecular Cancer Therapeutics,2002, 1 (3) 197-204, abstract.
Database CANCERLIT on STN (Columbus, OH) AN 83024743, Hacker M. et al., “Effect of disulfiram (tetraethylthiuram disulfide) and diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice”,Cancer Research,Nov. 1982, 42 (11) 4490-4, abstract.
Database (DRUGU on STN (Columbus, OH) AN 2002-25463, Cen D. et al., “Redox related apoptosis of melanoma cells”,Proc. Am. Assoc. Cancer Res.,43, 93 Meet., 532, 2002, abstract.
Nobel C.S. et al., Mechanism of dithiocarbamate inhibition of apoptosis: thiol oxidation by dithiocarbamate disulfides directly inhibits processing of the caspase-3 proenzyme,Chemical Research in Toxicology,Jun. 1997, vol. 10, No. 6, pp. 636-643.
Meshnick S.R. et al., Antimalarial activity of diethyldithiocarbamate. Potentiation by Copper,Biochemical Pharmacology,Jul. 15, 1990, vol. 40, No. 2, pp. 213-216.
HIV infection. Dithiocarb treatment in AIDS is unsuccessful,Fortschritte der Medizin,Nov. 20, 1991, vol. 109, No. 33, p. 18.
Daniel, K.G., et al., Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells,Breast Cancer Research,vol. 7, 2005, pp. R897-R908.
Disulfiram and Tumor Inhibition,H. K. A. Schirmer et al., Transactions of American Association of Genito-Urinary Surgeons, vol. 58, pp. 63-66, 1966.
Rostein et al., Carcinogenesis (London) (1988), 9(9), 1547-51.
Brar, S. Molecular Cancer Therapeutics, 2004; 3(9); pp. 1049-1060.
Lonnerda

Affiliated with

Also associated with

Rating

Method of inhibiting ATF/CREB and cancer cell growth and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of inhibiting ATF/CREB and cancer cell growth and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting ATF/CREB and cancer cell growth and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4215788